170 related articles for article (PubMed ID: 29385469)
1. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Selvaraj F; Princen F; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Gearry RB; Selby W; Bell SJ; Brown SJ; Connell WR
J Crohns Colitis; 2018 May; 12(6):653-661. PubMed ID: 29385469
[TBL] [Abstract][Full Text] [Related]
2. Effect of intestinal resection on quality of life in Crohn's disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Sparrow MP; Florin TH; Gibson PR; Debinski H; Gearry RB; Macrae FA; Leong RW; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Desmond PV
J Crohns Colitis; 2015 Jun; 9(6):452-62. PubMed ID: 25855073
[TBL] [Abstract][Full Text] [Related]
3. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
[TBL] [Abstract][Full Text] [Related]
4. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.
Zittan E; Kabakchiev B; Milgrom R; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
J Crohns Colitis; 2016 May; 10(5):510-5. PubMed ID: 26783345
[TBL] [Abstract][Full Text] [Related]
5. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
[TBL] [Abstract][Full Text] [Related]
6. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.
Plevris N; Lyons M; Jenkinson PW; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Shand AG; Din S; Arnott ID; Jones GR; Lees CW
Inflamm Bowel Dis; 2019 May; 25(6):1036-1043. PubMed ID: 30335139
[TBL] [Abstract][Full Text] [Related]
7. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
8. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
Nakase H; Motoya S; Matsumoto T; Watanabe K; Hisamatsu T; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T;
Aliment Pharmacol Ther; 2017 Nov; 46(9):873-882. PubMed ID: 28884856
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
10. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
11. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
13. Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease.
Zittan E; Steinhart AH; Goldstein P; Milgrom R; Gralnek IM; Silverberg MS
Clin Transl Gastroenterol; 2021 Oct; 12(10):e00401. PubMed ID: 34613952
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.
Aguas M; Bastida G; Cerrillo E; Beltrán B; Iborra M; Sánchez-Montes C; Muñoz F; Barrio J; Riestra S; Nos P
World J Gastroenterol; 2012 Aug; 18(32):4391-8. PubMed ID: 22969204
[TBL] [Abstract][Full Text] [Related]
16. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
Vande Casteele N; Baert F; Bian S; Dreesen E; Compernolle G; Van Assche G; Ferrante M; Vermeire S; Gils A
J Crohns Colitis; 2019 Sep; 13(10):1248-1256. PubMed ID: 30820530
[TBL] [Abstract][Full Text] [Related]
18. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis.
Cañete F; Mañosa M; Pérez-Martínez I; Barreiro-de Acosta M; González-Sueyro RC; Nos P; Iglesias-Flores E; Gutiérrez A; Bujanda L; Gordillo J; Ríos León R; Casanova MJ; Villoria A; Rodríguez-Lago I; López Serrano P; García-Herola A; Ramírez-de la Piscina P; Navarro-Llavat M; Taxonera C; Barrio J; Ramos L; Navarro P; Benítez-Leiva O; Calafat M; Domènech E;
Clin Transl Gastroenterol; 2020 Aug; 11(8):e00218. PubMed ID: 32955190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
